Skingen Biotech Mometasone Furoate

Skingen Biotech Mometasone Furoate



U Square Lifesciences


Skingen Biotech
Concise Prescribing Info
Mometasone furoate
Relief of inflammatory & pruritic manifestations of corticosteroid responsive dermatoses.
Dosage/Direction for Use
Apply to affected area in thin layers by smoothing gently into the skin preferably after bath once daily.
Hypersensitivity. Acute infections uncontrolled by appropriate antimicrobial therapy, ulcerative conditions, rosacea, pruritus. Childn <1 yr.
Special Precautions
Avoid contact w/ the eyes. Do not apply w/ an occlusive dressings to large areas of the body. Avoid long-term use especially in childn. Patients already receiving corticosteroids are more susceptible to infection.
Adverse Reactions
Loss of skin collagen, subcutaneous atrophy, local hypopigmentation of deeply pigmented skins, hypersensitivity reactions, mobilization of Ca & P, w/ osteoporosis & spontaneous fractures; muscle wasting & nitrogen depletion & hyperglycemia w/ accentuation or precipitation of the diabetic state. Increased insulin requirements in diabetic patients; increased appetite; impaired tissue repair & immune function, increased susceptibility to infection including septicemia, TB, fungal infections & viral infections; increased severity  of varicella & measles; menstrual irregularities, amenorrhoea, hyperhidrosis, skin thinning, ocular changes including glaucoma & cataract mental & neurological disturbances, benign intracranial HTN, acute pancreatitis & avascular necrosis of bone. Increased coagulability of the blood may lead to thromboembolic complications. Peptic ulceration.
Drug Interactions
Enhanced metabolism & reduced effects w/ barbiturates, carbamazepine, phenytoin, primidone or rifampicin. Increased plasma conc w/ OCs or ritonavir. Excessive K loss w/ K-depleting diuretics eg, thiazides or furosemide. Increased risk of hypokalemia w/ amphotericin B or bronchodilator therapy w/ xanthines or β2 agonists. Increased incidence of GI bleeding & ulceration w/ NSAIDs. Altered response to anticoagulants. Increased requirements of antidiabetic drugs & antihypertensives. Decreased serum conc of salicylates. Decreased effect of anticholinesterases in myasthenia gravis.
MIMS Class
Topical Corticosteroids
ATC Classification
D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
Skingen Biotech Mometasone Furoate cream 1 mg/g
15 g x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in